Skip to main content
보도자료 배포 뉴스와이어
검색폼
검색
로그인
회원가입
보도자료
서비스
교육
블로그
보도자료 배포
보도자료 구독
고객센터
보도자료 배포 서비스
보도자료 배포 뉴스와이어
보도자료 배포
보도자료 구독
고객센터
로그인
회원가입
보도자료
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
박람회
FAQ
취소
기업 검색
보도자료 등록
최신
IT
건강
경제
교육
금융
농수산
라이프
레저
문화
미디어
부동산
사회
산업
스포츠
에너지
운송
유통
자동차
정책
신상품
상장기업
주요
최신 보도자료
MY뉴스
상장기업
사진
동영상
기업뉴스룸
박람회
인기 토픽
보도자료 분야와 RSS
English News
산업별
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
미디어
산업별
부동산
사회
산업
스포츠
에너지/환경
운송
유통
자동차
정책/정부
주제별
개발
공모/모집
기업문화
부고
분양
사업계획
사회공헌
선언/의견
설립/오픈
소송
수상/선정
수주
주제별
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
제휴
조사연구
채용
투자
판촉활동
지역별
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
기업 뉴스룸
Boehringer Ingelheim International GmbH
이 회사 보도자료 구독
제약
INGELHEIM, Germany
http://www.boehringer-ingelheim.com
Boehringer Ingelheim International GmbH 보도자료
337개
RSS
이메일
2015년 6월 1일
10:00
ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 (https://goo.gl/6xNSFt) trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib* and erlotinib, in patients wi
건강
제약
개발
2015년 5월 29일
09:30
Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union
Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli
건강
제약
개발
2015년 5월 28일
10:45
Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance portfolio June 5-9 at the American Diabetes Association’s® (ADA) 75th Scientific Sessions in Boston. Th
건강
제약
행사
2015년 5월 27일
09:25
FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved as a long-term, once-daily maintenance treatment o
건강
제약
개발
2015년 5월 21일
11:55
New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy[1,2,3]
Boehringer Ingelheim today announced new data analyses from the pivotal Phase III TONADO® 1&2 studies[4] (NCT01431274, https://goo.gl/7NI8eq / NCT01431287, https://goo.gl/ug1HN1). Data showed tiotropium/olodaterol Respimat®‡ provided lung function be
건강
제약
개발
2015년 5월 18일
18:20
Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and t
건강
제약
개발
2015년 5월 18일
18:15
New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups
Boehringer Ingelheim announced new data and analyses for OFEV® (nintedanib*) reinforcing its efficacy, safety and tolerability in a broad range of patients with idiopathic pulmonary fibrosis (IPF). These findings were presented at the American Thorac
건강
제약
개발
2015년 5월 14일
15:45
Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung
Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, 29 May - 2 June 2015. A total of 9 abstracts, including
건강
제약
개발
2015년 5월 14일
11:40
First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation
The first patient with atrial fibrillation (AF) has been enrolled in the global RE-CIRCUIT™ study.[4] The study assesses the safety and efficacy of uninterrupted anticoagulation with dabigatran etexilate (Pradaxa®) during ablation procedures compared
건강
제약
개발
2015년 4월 20일
10:15
New international survey of lung cancer oncologists highlights underutilization of personalized treatments
For media outside the US, the UK and Canada only Results from a new global survey of lung cancer oncologists have shown that despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for EGFR mutations, a sig
건강
제약
개발
2015년 4월 14일
10:35
Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders
Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP) channel modulation, and Boehringer Ingelheim today announced that they have entered into a worldwide research collaboration and license agreement to identify small-m
건강
제약
제휴
2015년 3월 30일
16:15
Type 2 Diabetes: CHMP Recommends Empagliflozin/Metformin Hydrochloride for Approval in the European Union
For media outside the US, the UK and Canada only Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) today announced they have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medic
건강
제약
개발
2015년 3월 17일
10:20
Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces two analyses from the GLORIA™-AF Registry Program examining the use of anticoagulant treatments for stroke prevention in patients with atrial fibrillation (AF).[1,2] These n
건강
제약
개발
2015년 3월 4일
10:15
Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and Health Canad
건강
제약
개발
2015년 1월 27일
17:30
New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD
For media outside the US, the UK and Canada Boehringer Ingelheim today announced that the first patient has been enrolled into its large-scale DYNAGITO® study.[1] It will assess the potential benefit of tiotropium + olodaterol Respimat® FDC† compa
건강
제약
개발
2015년 1월 19일
17:45
OFEV® (nintedanib*) approved in the EU for the treatment of IPF
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014. Nintedanib* will be
건강
제약
개발
2015년 1월 15일
10:45
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim announced today that it has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory of Professor Stephen W. Fesik, Ph.D., the Orrin H. Ingram, II Chair in Cancer Research and Professor
건강
제약
제휴
2015년 1월 14일
11:25
Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas
Boehringer Ingelheim announced today collaboration with Yale University, New Haven, Connecticut, USA, with the goal of researching novel therapeutic targets in the field of immune-modulation. Immune-modulation refers to a range of treatments aimed at
건강
제약
제휴
2015년 1월 12일
16:40
The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy
Boehringer Ingelheim today announced overall survival (OS) results were published in The Lancet Oncology from two independent Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6) in epidermal growth factor receptor (EGFR) mutation-positive patients
건강
제약
개발
2014년 12월 16일
09:55
First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investigate the efficacy and safety of dabigatran etexilate for the prevention of recurrent Embol
건강
제약
개발
2014년 12월 9일
17:50
New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers
For Non-US/Non-UK/Non-Canadian Media New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexi
건강
제약
개발
2014년 11월 27일
17:50
Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy
For media outside UK, US and Canada only Today Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for Vargatef® (nintedanib*), valid for the 28 countries within the EU. Vargatef® in combination with
건강
제약
개발
2014년 11월 24일
16:10
Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF
For media outside UK, US and Canada Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for nintedanib* (suggested brand name OFEV
건강
제약
개발
2014년 11월 19일
18:45
New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans
For Non-US/Non-UK/Non-Canadian Media New data on the investigational antidote idarucizumab show that it can reverse the effect of the oral anticoagulant Pradaxa® (dabigatran etexilate) on both blood coagulation and the blood clotting mechanism. In
건강
제약
개발
2014년 11월 19일
18:40
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin
For Non-US/Non-UK/Non-Canadian Media Two new real-world data analyses presented at the American Heart Association’s Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with
건강
제약
개발
이전
9
10
11
12
13
다음
동영상
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기